Skip to main content

Start saving
on EYSUVIS

Stop spending money on drops that don’t target the cause of your symptom flare‑ups and start saving on something that does.

Enroll and get/activate your Co‑pay
Card today to start saving.

EYSUVIS® (loteprednol etabonate ophthalmic suspension) savings card

The EYSUVIS 'I SAVE' Patient Access Program where patients can expect to:

PAY AS LITTLE AS $40

for patients whose commercial insurance covers EYSUVIS.

PAY AS LITTLE AS $60

for patients whose commercial insurance does not cover EYSUVIS.

FIND OUT IF YOU'RE ELIGIBLE

Contact us

For additional information or to report an adverse event, call Kala Pharmaceuticals, Inc. at 1‑833‑287‑KALA
(1‑833‑287‑5252).

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit , or call 1‑800‑FDA‑1088.

Sign up for updates

Want to know more about EYSUVIS? Register your email to get updates and information on the drop that’s there for the flare.

* In a clinical trial program with 2871 patients with dry eye, patients using EYSUVIS showed significant reduction in the symptoms of dry eye (ocular discomfort) as early as Day 4 after starting treatment (versus placebo). Symptoms continued to improve up to the end of the treatment period (Day 15). Patients taking EYSUVIS also showed significant reduction in signs of dry eye (eye redness) at Day 15 versus placebo.

Eligible patients only. Terms & conditions apply.